Biocon is currently trading at Rs. 459.85, up by 4.55 points or 1.00% from its previous closing of Rs. 455.30 on the BSE.
The scrip opened at Rs. 459.85 and has touched a high and low of Rs. 459.85 and Rs. 456.60 respectively.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 477.90 on 09-Oct-2020 and a 52 week low of Rs. 235.80 on 19-Mar-2020.
Last one week high and low of the scrip stood at Rs. 460.65 and Rs. 447.00 respectively. The current market cap of the company is Rs. 54636.00 crore.
The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 22.98% and 16.35% respectively.
Biocon’s subsidiary company -- Biocon Biologics, in continuation of its Mission 10 cents affordable insulins program for low- and middle-income countries (LMICs), has signed a Memorandum of Understanding (MoU) with the Christian Social Services Commission (CSSC), a faith-based organization active in Africa. CSSC works closely with the government as well as international and national partners to facilitate health and education services. Tanzania will be the first country in Africa that will benefit from this collaboration between Biocon Biologics and CSSC.
As a leading global insulins player, Biocon Biologics is helping unlock universal access to quality insulins in low- and middle-income countries (LMICs) by making recombinant human insulin (rh-insulin) available for less than 10 U.S. cents per day as a part of its ‘Mission 10 cents’ program. Besides improving access to insulin treatment by making affordable yet high quality insulin available, Biocon Biologics is working with local partners to help strengthen overall healthcare capacity with the aim of supporting all people with diabetes in LMICs, where diabetes prevalence has been rising more rapidly than in high-income countries.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: